Eric L. Sievers

14.6k citations
101 papers · 10.3k · 8 hit papers · h-index 38

Impact in

Papers in

    • HER2/EGFR in Cancer Research 15
    • CAR-T cell therapy research 11
    • Acute Myeloid Leukemia Research 27
    • Hematopoietic Stem Cell Transplantation 10

Eric L. Sievers

98 papers receiving 10.0k citations

Eric L. Sievers's Hit Papers

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial 2015 · 482 citations
4820+8+16Years since publication2505007501000

Peers

Eric L. Sievers
Comparison fields: 5 of 116
  • Hematology 2.3k
  • Pathology and Forensic Medicine 3.1k
  • Oncology 4.5k
  • Genetics 1.1k
  • Radiology, Nuclear Medicine and Imaging 2.2k
Replace Myron S. Czuczman with:
Myron S. Czuczman United States
Thomas M. Grogan United States
Bruce D. Cheson United States
Michinori Ogura Japan
Steven Le Gouill France
Alessandro Pileri Italy
Marco Bregni Italy
Franck Morschhauser France
Sven de Vos United States
Hans Tesch Germany
Eric L. Sievers relative to Myron S. Czuczman United States Myron S. Czuczman's profile →
Citations per field
00.5×1.5×2.0×
Myron S. Czuczman · 1×
Citations per year

Countries citing papers authored by Eric L. Sievers

Since Specialization
Citations

This map shows the geographic impact of Eric L. Sievers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric L. Sievers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric L. Sievers more than expected).

Fields of papers citing papers by Eric L. Sievers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric L. Sievers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric L. Sievers. The network helps show where Eric L. Sievers may publish in the future.

Co-authors

The 25 scholars most cited alongside Eric L. Sievers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eric L. Sievers Line = papers co-authored together Eric L. Sievers links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 101 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Hit paper breakdown →
20121026
2
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Hit paper breakdown →
2010967
3
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Hit paper breakdown →
2012719
4
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
Hit paper breakdown →
2001660
5
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Hit paper breakdown →
2001632
6
Antibody-Drug Conjugates in Cancer Therapy
Hit paper breakdown →
2012600
7
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Hit paper breakdown →
2012585
8
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Hit paper breakdown →
2015482
9 1999340
10 2005325
11 1999312
12 2010293
13 2009192
14 2002169
15 2002168
16 2011161
17 2006161
18 2001160
19 2014158
20 2002156

About Eric L. Sievers

Eric L. Sievers is a scholar working on Oncology, Hematology, Pathology and Forensic Medicine, Immunology and Molecular Biology, having authored 101 papers that have together received 10.3k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (27 papers), Lymphoma Diagnosis and Treatment (26 papers), HER2/EGFR in Cancer Research (15 papers), Monoclonal and Polyclonal Antibodies Research (11 papers), CAR-T cell therapy research (11 papers), Hematopoietic Stem Cell Transplantation (10 papers), Immunotherapy and Immune Responses (8 papers) and Neuroblastoma Research and Treatments (7 papers). The work is most often cited by research in Hematology (2.3k citations), Pathology and Forensic Medicine (3.1k citations), Oncology (4.5k citations), Genetics (1.1k citations) and Radiology, Nuclear Medicine and Imaging (2.2k citations). Eric L. Sievers has collaborated with scholars based in United States, South Africa and Canada. Frequent co-authors include Peter D. Senter, Dana A. Kennedy, Nancy L. Bartlett, Andres Forero‐Torres, Anas Younes, Joseph D. Rosenblatt, John P. Leonard, Irwin D. Bernstein, Carmel M. Lynch and Joseph M. Connors. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Clinical Cancer Research and Current Opinion in Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact